๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.

RecruitingNAAges 55 Years - 85 YearsAllUniversitaire Ziekenhuizen KU Leuven
NCT07666113 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aฮฒ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns. Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status. Exclusion Criteria: * Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure). * Concomitant medications that would interfere with cognitive assessments. * A prior diagnosis of AD and related disorders or other neurodegenerative disease.
๐Ÿ’Š

What it tests

  • ptau217
๐Ÿ“

Where

1 site
UZ Leuven/KU Leuven
Leuven, Belgium
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy